CVS Health Corporation

CVS Health Corporation Earnings Recaps

CVS Health Care 4 recaps
Next earnings: February 9, 2027 (estimated) · full calendar
Q3 2026 Nov 5, 2026

CVS shares fell 12.5% despite higher 2026 guidance, suggesting investors focused on the uncertainty and execution risks around the announced separation into two companies. The excerpt also flags healthcare cost trends that remain elevated, though management said they were broadly in line with expectations.

Key takeaways
  • CVS reported $108 billion in quarterly revenue, $4.2 billion in adjusted operating income, and adjusted EPS of $2.09, up more than 30% year over year.
  • Management raised 2026 adjusted EPS guidance to at least $8.20, from a prior range of $7.90–$8.10, and cash flow from operations guidance to at least $15.5 billion.
  • Healthcare Benefits generated $900 million in adjusted operating income; its 91.3% medical benefit ratio improved about 150 basis points year over year. Medical cost trends remained above historical levels.
  • Health Services adjusted operating income rose nearly 3% to $2.1 billion, while Pharmacy and Consumer Wellness operating income increased more than 10% to over $1.6 billion.
  • CVS announced plans to separate into a healthcare solutions company and a retail pharmacy and community healthcare company; the call excerpt does not specify the separation’s timeline or financial implications.
Q2 2026 Aug 8, 2026

CVS Health's stock fell 7.9% following the earnings release as investors were disappointed by signs of deceleration in key segments and cautious outlook indicators, despite management’s emphasis on growth initiatives and raised full-year guidance.

Key takeaways
  • Adjusted operating income was $5.2 billion and adjusted EPS of $2.58 for the quarter.
  • Management raised full year adjusted EPS guidance to a range of $7.90 to $8.10 and increased expected cash flow from operations by $2 billion to at least $11.5 billion.
  • GLP-1 therapies continue to drive business focus, with pricing initiatives and direct-to-consumer channels aiming to address affordability and access challenges.
  • Continued investment in digital platforms like the Health100 and AI assistant Haio targets improved consumer engagement but early impact remains uncertain.
  • Operational improvements include AI-enabled claims processing and expanded clinical collaboration, but incremental near-term benefits may be limited amid slower growth dynamics.
Q1 2026 May 7, 2026

CVS Health's shares rose 8.2% following a better-than-expected quarter marked by an increased full-year adjusted EPS guidance and strong operational execution across segments.

Key takeaways
  • Reported adjusted operating income of $5.2 billion and adjusted EPS of $2.57 for Q1 2026.
  • Raised full-year adjusted EPS guidance to $7.30–$7.50, up from $7.00–$7.20.
  • Continued focus on lowering net costs via pharmacy benefits management, exemplified by $25 insulin pricing across 60,000+ pharmacies.
  • Accelerating biosimilar adoption by excluding branded STELARA from commercial formularies starting July 1, leveraging prior success with HUMIRA conversions.
  • Maintained industry leadership in prior authorization efficiency, with over 95% approvals within 24 hours and 88% of PA procedures standardized today.
Q3 2025 Oct 29, 2025

CVS Health reported strong third-quarter results with adjusted earnings per share rising to $1.60, prompting an increase in full-year guidance. The diversified business strategy shows promise, despite challenges in Health Care Delivery.

Key takeaways
  • Adjusted operating income reached $3.5 billion, reflecting robust performance across the enterprise.
  • Full-year adjusted earnings per share guidance revised upwards to $6.55–$6.65 from the previous range of $6.30–$6.40.
  • Aetna continues to excel, leading in Medicare Advantage Stars Ratings with over 81% of members in 4-star plans or higher.
  • A $5.7 billion goodwill impairment was recorded due to restrained growth expectations for Oak Street Health, underscoring the need for strategic adjustments.
  • While navigating challenges in Pharmacy Services, CVS remains committed to drug cost transparency and innovative pricing models for consumers.